Levin Ilan bought SLXN

September 15, 2025 · Form 4 insider transaction

Levin Ilan bought 450,000 shares of Silexion Therapeutics Corp at $4.00 per share, a transaction worth $1.80M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 134 days after the transaction.

Direction
Acquired (buy-side)
Shares
450,000
Price
$4.00
Total value
$1.80M
InsiderLevin Ilan
Role
SecurityOrdinary Shares
Transaction codeA: Grant or award
Transaction dateSeptember 15, 2025
Filing dateJanuary 27, 2026
Shares owned after456,970
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares.; The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.; Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein.

View the original Form 4 on SEC EDGAR